Wet Age-Related Macular Degeneration: Sizing the commercial potential.
By Hardik Patel, Lead Analyst
7 August 2014
I am Lead Analyst for oncology at Datamonitor Healthcare, based in the New York office. I have a Bachelor of Science deg...
Read full bio
During 2014−23, the wet age-related macular degeneration (AMD) market is forecast to expand at a compound annual growth rate of 3.43%. This growth coincides with the anticipated launch of pipeline candidate Fovista in 2017. Datamonitor Healthcare has used a patient-based approach to size the commercial potential of wet AMD across the US and five major EU markets, giving you key insights into the wet AMD market.
How will our wet AMD forecast report benefit you?
- Predict market share
View the impact of events such as reimbursement changes for off-label use of Avastin in the EU, allowing you to track market share shift in wet AMD.
- Understand drivers behind market growth
Take an in-depth look into how the value of the market will change over the forecast period and what catalysts are influencing these changes, enabling you to prepare for change within the market and use these drivers where possible.
- Identify investment opportunity
Recognize which drugs will attract the most biosimilar competition once patents expire, which classes of drugs will produce the most growth, and where future unmet needs may lie within the market in order to target areas with the most potential.
Key questions answered
- How will the launch of pipeline therapy Fovista affect market growth?
- What market share will biosimilar versions of VEGF inhibitors occupy by 2023?
- Which treatment is popular in each different geographical market?
|Drug List:||Companies Mentioned:|
Posted in Immunology and Inflammation.